
Duane Morris

DUANE MORRIS LLP
101 WEST BROADWAY, SUITE 900
SAN DIEGO, CA 92101
PHONE: 619.744.2200
FAX: 619.744.2201

FACSIMILE TRANSMITTAL SHEET

TO: Examiner Maury A. Audet

FIRM/COMPANY: United States Patent and Trademark Office

FACSIMILE NUMBER: 571.273.0960

**CONFIRMATION
TELEPHONE:**

FROM: James W. Collett, Ph.D.

DIRECT DIAL: 619.744.2240

DATE: September 29, 2006

USER NUMBER: 7348

FILE NUMBER: E5106-00005, ~~10/541,343~~

TOTAL # OF PAGES: 6
(INCLUDING COVERSHEET)

MESSAGE: Please see attached.

NOTE: Original will not follow

CONFIDENTIALITY NOTICE

THIS FACSIMILE TRANSMISSION IS PRIVILEGED AND CONFIDENTIAL AND IS INTENDED ONLY FOR THE REVIEW OF THE PARTY TO WHOM IT IS ADDRESSED. IF YOU HAVE RECEIVED THIS TRANSMISSION IN ERROR, PLEASE IMMEDIATELY TELEPHONE THE SENDER ABOVE TO ARRANGE FOR ITS RETURN, AND IT SHALL NOT CONSTITUTE WAIVER OF THE ATTORNEY-CLIENT PRIVILEGE.

If there is a problem with this transmission, please call us as soon as possible at 619.744.2200.

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

CHAU, Raymond Ming Wah

Serial No.: 10/541,343

Filed: July 5, 2003

For: MNTF PEPTIDES AND
COMPOSITIONS AND METHODS OF USE

Customer No.: 53897

Confirmation No.: 8965

Group Art Unit: 1654

Examiner: AUDET, Maury A.

Docket No.: E5106-00005

I HEREBY CERTIFY THAT ON THE DATE INDICATED BELOW THIS CORRESPONDENCE (AND ANYTHING REFERRED TO AS BEING TRANSMITTED HEREWITH) IS BEING FACSIMILE TRANSMITTED TO THE UNITED STATES PATENT AND TRADEMARK OFFICE (FAX NO. 571-273-0960) ON THE DATE SHOWN BELOW

9/29/06
September 29, 2006

Jose R. Lopez, Jr.
Jose R. Lopez, Jr.

RESPONSE AND AMENDMENT

Attn: Examiner Maury A. Audet
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This communication is filed in response to the Office Action dated September 11, 2006. No fee is believed due because this response is timely filed within the period for response which is up to and including December 11, 2006 without an extension of time. Applicants request that the United States Patent and Trademark Office consider the following remarks and remove the pending restriction requirement for the following reasons.

Amendments to the Claims begin on page 2 of this paper.

Remarks begin on page 4 of this paper.

Summary begins on page 5 of this paper.